$ABVX

Abivax S.A.

Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body’s natural regulatory mechanisms. Its initial focus is inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Abivax’s lead drug candidate, obefazimod, is an oral small molecule in Phase 3 clinical development for moderately to severely active ulcerative colitis and is also being developed for Crohn’s disease. The company is evaluating potential combination therapies and developing follow-on compounds based on its miR-124 platform. Abivax aims to develop and commercialize obefazimod. It holds worldwide rights and may pursue strategic partnerships in certain geographies, with potential upfront funding, milestone payments and royalties. Abivax is headquartered in Paris, France, and has one wholly owned subsidiary, Abivax LLC.

No enriched coverage for $ABVX in the last 7 days.

No SEC Form 4 filings for $ABVX in the last 30 days.

See all $ABVX insider activity →
Med

Piper Sandler reiterates Abivax stock rating on trial data

Piper Sandler reiterated an Overweight rating and $175 price target for Abivax (ABVX) after positive trial data. The firm highlighted obefazimod's strong endoscopic-remission profile in inflammatory bowel disease. ABVX shares have fallen 30% since August, trading at $94.21. Analysts' price targets range from $142 to $181. Goldman Sachs initiated coverage with a Buy rating and $155 target, citing obefazimod's potential in ulcerative colitis.

ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?

ABIVAX (ABVX) reported a 54% increase in operating cash use to €102.5M in H1 2026, with €1.2B in total liquidity post-equity financing. The company projects funds will last until Q4 2029, supporting its planned U.S. drug application for obefazimod by year-end. Investors focus on spending efficiency and regulatory progress.

ABVX sentiment & insider activity

Recent ABVX coverage spans financial news, earnings and corporate actions.

What's driving ABVX

AlphAI scores every news story that mentions ABVX with an AI model for sentiment and relevance, and aggregates insider trades from Abivax S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ABVX

Score

Piper Sandler reiterates Abivax stock rating on trial data

Piper Sandler reiterated an Overweight rating and $175 price target for Abivax (ABVX) after positive trial data. The firm highlighted obefazimod's strong endoscopic-remission profile in inflammatory bowel disease. ABVX shares have fallen 30% since August, trading at $94.21. Analysts' price targets range from $142 to $181. Goldman Sachs initiated coverage with a Buy rating and $155 target, citing obefazimod's potential in ulcerative colitis.

EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.

$ABVXHighEarnings

Abivax S.A. (ABVX): Financial results for H1 2026

Abivax S.A. (ABVX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Abivax Presents Business Updates and First Half 2026 Financial Results • Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and

This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - SM

Analysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.

Here are Thursday's biggest analyst calls: Nvidia, SpaceX, Tesla, Ferrari, Meta, Apple, AMD, Yum & more

Analysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.

$ABVXMedAI 8/10

ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears

Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.

Related tickers